TopAlliance Biosciences
在场
TopAlliance Biosciences 的所有者是 Junshi Biosciences.
是其中之一......
Junshi Biosciences 是一家在股票代码 688180 (HK) 下上市的公司。
高管
查看带有其 13 名主要高管的组织结构图
TopAlliance Biosciences 搜索最多的简介
高管在Junshi Biosciences变化
- Li Zhongxian已作为Independent Non-Executive Directors加入公司 (新闻发布的2024十二月3号).
- Lu Kun已作为Independent Non-executive Directors加入公司 (新闻发布的2024十二月3号).
- Meng Anming, Independent Non-Executive Director, 已经离开公司 (新闻发布的2024十二月3号).
创建提醒
跟踪 TopAlliance Biosciences 的高管变动
生物技术
Junshi Biosciences 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
TopAlliance Biosciences 的最新新闻稿
- News Releases
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 | Eli Lilly and Company
- Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
- View more press releases Close
通过电子邮件
